Practical Recommendations for Diagnosis and Management of Respiratory Muscle Weakness in Late-Onset Pompe Disease

Matthias Boentert1, Hélène Prigent2, Katalin Várdi3

  • 1Department of Sleep Medicine and Neuromuscular Disorders, Münster University Hospital, Münster 48149, Germany. matthias.boentert@ukmuenster.de.

Insights

Pompe disease causes progressive muscle weakness, particularly affecting breathing. Early detection and management of respiratory issues are vital for improving survival in late-onset Pompe disease patients.

Area of Science:

  • Neurology
  • Pulmonology
  • Genetics

Background:

  • Pompe disease is a genetic disorder causing progressive muscle weakness.
  • Respiratory muscle dysfunction is a significant complication in late-onset Pompe disease.
  • Weakness impacts breathing, cough, and increases infection risk.

Purpose of the Study:

  • To provide expert recommendations for diagnosing and managing respiratory muscle involvement in late-onset Pompe disease.
  • To highlight the critical need for multidisciplinary care in managing respiratory complications.

Main Methods:

  • Review of clinical experience with over 200 patients.
  • Development of practical guidelines for respiratory care.

Main Results:

  • Respiratory muscle weakness can progress faster than other neurological deficits.
  • Sleep-disordered breathing, hypercapnia, and ventilation needs are common.
  • Respiratory compromise is a major cause of mortality despite treatment.

Conclusions:

  • Effective management of respiratory muscle weakness is crucial for Pompe disease patient outcomes.
  • A collaborative approach involving neurologists, pulmonologists, and intensivists is essential.
  • Early detection and intervention improve patient care and survival.

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.9K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
434
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
1.1K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
999